Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

FDA Consumer Health Information: Allergy Relief For Your Child

U.S. Food and Drug Administration

News provided by

U.S. Food and Drug Administration

May 26, 2016, 10:47 ET

Share this article

Share toX

Share this article

Share toX

SILVER SPRING, Md., May 26, 2016 /PRNewswire-USNewswire/ -- View this consumer update on FDA's website: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm273617.htm

Children are magnets for colds. But when the sniffles and sneezing won't go away for weeks, the culprit may be something else: allergies.

Long-lasting sneezing, with a stuffy or runny nose, may signal the presence of allergic rhinitis—the collection of symptoms that affect the nose when you have an allergic reaction to something you breathe in and that lands on the lining inside the nose.

Allergies may be seasonal or they can strike year-round (perennial). In most parts of the United States, plant pollens are often the cause of seasonal allergic rhinitis—more commonly called hay fever. Indoor substances, such as mold, dust mites, and pet dander, may cause the perennial kind.

Up to 40 percent of children suffer from allergic rhinitis, according to the National Institute of Allergy and Infectious Diseases (NIAID). And children are more likely to develop allergies if one or both parents have allergies.

The U.S. Food and Drug Administration (FDA) regulates both over-the-counter (OTC) and prescription medicines that offer allergy relief as well as allergen extracts used to diagnose and treat allergies. And parents should take particular care when giving these products to children.

Immune System Reaction

An allergy is the body's reaction to a specific substance, or allergen. Our immune system responds to the invading allergen by releasing histamine and other chemicals that typically trigger symptoms in the nose, lungs, throat, sinuses, ears, eyes, skin, or stomach lining.

In some children, allergies can also trigger symptoms of asthma—a disease that causes wheezing or difficulty breathing.

If a child has allergies and asthma, "not controlling the allergies can make asthma worse," says Anthony Durmowicz, M.D., a pediatric pulmonary doctor in FDA's Division of Pulmonary, Allergy, and Rheumatology Products.

Avoiding the Culprit

If your child has seasonal allergies, you may want to pay attention to pollen counts and try to keep your child inside when the levels are high.

  • In the late summer and early fall, during ragweed pollen season, pollen levels are highest in the morning.
  • In the spring and summer, during the grass pollen season, pollen levels are highest in the evening.
  • Some molds, another allergy trigger, may also be seasonal. For example, leaf mold is more common in the fall.
  • Sunny, windy days can be especially troublesome for pollen allergy sufferers.

It may also help to keep windows closed in your house and car and run the air conditioner.

Allergy Medicines

For most children, symptoms may be controlled by avoiding the allergen, if known, and using OTC medicines. But if a child's symptoms are persistent and not relieved by OTC medicines, it is wise to see a health care professional to assess your child's symptoms and see if other treatments, including prescription medicines, may be appropriate. There are seven options available to help bring your child relief. Although some allergy medicines are approved for use in children as young as 6 months, Dianne Murphy, M.D., director of FDA's Office of Pediatric Therapeutics, has some cautions. "Always read the label to make sure the product is appropriate for your child's age," Murphy says. "Just because a product's box says that it is intended for children does not mean it is intended for children of all ages."

Another reason to carefully read the label is that even though the big print may say the product is for a certain symptom (sneezing, allergy, cough, etc.), different products may have the same medicine (active ingredient). So it might seem that you are buying different products to treat different symptoms, but in fact the same medicine could be in all the products. The result: You might accidently be giving too much of one type of medicine to your child.

"Children are more sensitive than adults to many drugs," adds Murphy. "For example, some antihistamines can have adverse effects at lower doses on young patients, causing excitability or excessive drowsiness."

More Child-Friendly Medicines

Recent pediatric legislation, including a combination of incentives and requirements for drug companies, has significantly increased research and development of drugs for children and has led to more products with new pediatric information in their labeling. Since 1997, a combination of legislative activities has helped generate studies in children for 600 products.

Many of the older drugs were only tested in adults, says Durmowicz. "But we now have more information available for the newer allergy medications," he adds. "With the passing of this legislation, there should be more confidence in pediatric dosing and safety with the newer drugs."

The legislation also requires drugs for children to be in a child-friendly formulation, adds Durmowicz. So if the drug was initially developed as a capsule, it has to also be made in a form that a child can take, such as a liquid with cherry flavoring, rapidly dissolving tablets, or strips for placing under the tongue.

In February 2016, FDA approved a generic version of Flonase Allergy Relief, an over-the-counter-allergy symptom reliever nasal spray for the temporary relief of the symptoms of hay fever or other upper respiratory allergies.  In March 2016, FDA approved the first generic version of Nasonex spray for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 2 and older.

Allergy Shots

Jay E. Slater, M.D., director of FDA's Division of Bacterial, Parasitic and Allergenic Products, who is also a pediatric allergist says that children who don't respond to either OTC or prescription medications, or who suffer from frequent complications of allergic rhinitis, may be candidates for allergen immunotherapy—commonly known as allergy shots. According to NIAID, about 80 percent of people with allergic rhinitis will see their symptoms and need for medicine drop significantly within a year of starting allergy shots.

After allergy testing, typically by skin testing to detect what allergens your child may react to, a health care professional injects the child with "extracts"—small amounts of the allergens that trigger a reaction. The doses are gradually increased so that the body builds up immunity to these allergens.

Allergen extracts are manufactured from natural substances, such as pollens, insect venoms, animal hair, and foods. More than 1,200 extracts are licensed by FDA.

In 2014, FDA approved three new immunotherapy products to be taken under the tongue for treatment of hay fever caused by certain pollens, two of them for use in children. All of them are intended for daily use, before and during the pollen season. They are not meant for immediate symptom relief. Although they are intended for at-home use, these are prescription medications, and first doses are to be taken in the presence of a health care provider. The products are Oralair, Grastek, and Ragwitek (which is approved for use in adults only).

"Allergy shots are never appropriate for food allergies," adds Slater, "but it's common to use extracts to test for food allergies so the child can avoid those foods."

Transformation in Treatment

"In the last 20 years, there has been a remarkable transformation in allergy treatments," says Slater. "Kids used to be miserable for months out of the year, and drugs made them incredibly sleepy. But today's products offer proven approaches for relief of seasonal allergy symptoms."

Forgoing treatment can make for an irritable, sleepless, and unhappy child, adds Slater, recalling a mother saying after her child's successful treatment, "I didn't realize I had a nice kid!"

FDA-Approved Options for Treatment of Allergic Rhinitis (Hay Fever) in Children

Drug Type

How Used

Some Examples of Over-the-Counter (OTC) or Prescription (Rx) Drugs (many are available in generic form)

Common Side Effects

 

Nasal corticosteroids

 

Usually sprayed in nose once a day

 

Rx:

  • Nasonex (mometasone furoate)
  • Flonase (fluticasone propionate)

OTC:

  • Nasacort Allergy 24HR (triamcinolone acetonide)
  • Rhinocort Allergy Spray (budesonide)
  • Flonase Allergy Relief (fluticasone propionate)

 

Stinging in nose

 

Oral and topical antihistamines

 

Orally (pills, liquid, or capsules), nasally (spray or drops), or eye drops

 

Oral OTC:

  • Benadryl (diphenhydramine)
  • Chlor-Trimeton (chlorpheniramine)
  • Allegra* (fexofenadine)
  • Claritin* (loratadine)
  • Zyrtec (cetirizine)

Oral Rx:

  • Clarinex (desloratadine)

Nasal Rx:

  • Astelin (azelastine)

* non-sedating when taken as directed

 

Some antihistamines may cause drowsiness

 

 

Some nasal sprays may cause a bitter taste in mouth, headache, and stinging in nose

 

Decongestants

 

Orally and nasally (sometimes taken with antihistamines, which used alone do not treat nasal congestion)

 

Oral Sudafed (pseudoephedrine*), Sudafed PE (phenylephrine)

Oral OTC:

  • Allegra D, which has both an antihistamine (fexofenadine) and decongestant (pseudoephedrine*)
  • Claritin D (loratadine; pseudoephedrine)
  • Zyrtec D (cetirizine; pseudoephedrine)

Nasal OTC:

  • Neo-Synephrine (phenylephrine)
  • Afrin (oxymetazoline)

* Drugs that contain pseudoephedrine are non-prescription but are kept behind the pharmacy counter because of their illegal use to make methamphetamine. You'll need to ask your pharmacist and show identification to buy these drugs.

 

Using nose sprays or drops more than a few days may cause "rebound" effect, in which nasal congestion gets worse

 

Non-steroidal nasal sprays

 

Nasally used 3–4 times a day

 

OTC:

  • NasalCrom (cromolyn sodium)

Rx:

  • Atrovent (ipratropium bromide)

 

Stinging in nose or sneezing; can help prevent symptoms of allergic rhinitis if used before symptoms start

 

Leukotriene receptor antagonist

 

Orally once a day (comes in granules to mix with food, and chewable tablets)

 

Rx:

  • Singulair (montelukast sodium)

 

Headache, ear infection, sore throat, upper respiratory infection

Sublingual Immunotherapy

Tablet placed under the tongue daily- before and during allergy season

Rx:

  • Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract)

  • Grastek (Timothy Grass Pollen Allergen Extract)

 

Itching and swelling in the mouth and throat irritation

 

Itching and swelling in the mouth and throat irritation

Subcutaneous immunotherapy

Injections, weekly to monthly

  • Multiple

Itching and swelling at the injection site

This article appears on FDA's Consumer Updates page, which features the latest on all FDA-regulated products:  http://www.fda.gov/ForConsumers/ConsumerUpdates/default.htm.

FDA Office of Media Affairs
[email protected]
1-888-INFO-FDA

Logo - http://photos.prnewswire.com/prnh/20151222/317925LOGO

SOURCE U.S. Food and Drug Administration

Related Links

http://www.fda.gov

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

FDA Roundup: March 28, 2025

FDA Roundup: March 28, 2025

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA's Learning and...

FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Children

Children

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.